From HTA and pricing to procurement and HEOR, we help pharma and medtech companies build the evidence, dossiers, and strategies that earn favorable reimbursement and sustained market access.
Eight connected capabilities that help pharma and medtech teams turn clinical value into a clear, defensible market access strategy. Some clients use all of them as one program, others come to us for a single piece.
Every HTA body sets its own rules, and they differ by market and by product type. We help teams learn what each authority expects, assess their evidence against those requirements, and identify gaps before reimbursement discussions begin.
A price has to make sense next to a product's clinical profile, its competitors, what payers are willing to fund, and what each health system can afford. That looks different in every priority market. We help clients bring those factors together into a pricing approach their commercial teams can use and defend.
Payers and providers increasingly look beyond clinical efficacy. They want to know what a product does for outcomes, what it does to costs elsewhere in the system, and what it changes for patients day to day. We help clients pin down that value and present it so payers, providers, and patients can each follow it.
Endpoints, comparators, and patient populations get chosen early, and payers will question those choices years later. We help clients plan trials with that in mind, so the regulatory, operational, and analysis decisions all lead to data that payers can actually use.
Reimbursement rules change from one country to the next, and sometimes from one payer to the next. We help clients understand how their product is likely to be assessed in each target market, shape the value story and pricing that go with it, and keep tracking after launch so they can adjust as things change.
Buyers negotiate hard on cost, supply, and terms, and the way an organization buys affects both its margins and its stability. We help clients review how procurement works, design a better model, and manage supplier relationships and risk in line with their business goals.
Payers and HTA bodies ask for efficacy, safety, cost effectiveness, and real world results. Most teams have some of that, but rarely all of it. We help clients identify which evidence is still missing, support the research needed to address those gaps, and develop the findings in a form the people assessing them can use.
HEOR puts numbers on value: what an intervention costs, what it delivers, and how it compares with the alternatives. We build the economic models, budget impact analyses, and comparative studies that back up our clients' value cases and inform how their products are positioned.
Fix a market access problem late and it costs more: more time, more money, and less leverage with payers. Fix it while a team is still shaping clinical development or getting ready for a first HTA submission, and it’s usually a small job.
When we are involved before pricing, reimbursement, or post launch access become pressing, the evidence and the decisions are already in place when those questions arrive.
Assessments projected in 2026: 55
Scientific-advice slots available: 17
35 new oncology substances, 15 ATMPs and 5 high-risk devices and diagnostics are due a joint assessment this year, against a ceiling of 17 advice slots. Year one landed short of plan: about 25 assessments opened in 2025, 12 completed.We help teams assess the evidence, payer expectations, and market dynamics behind high stakes access decisions before timelines become constrained.
Practical thinking on evidence, payer engagement, pricing, and evolving access models.
Learn how one assessment across 27 markets is influencing drug launch strategies across the EU.
Examine how MFN pricing is changing global drug pricing and market access.
How our competitive intelligence helped a global biologic manufacturer strengthen patient access in NSCLC.
Explore how real-world evidence can support rare disease development from early trials to market access.
HTA preparation, evidence planning, pricing, reimbursement, procurement: tell us where you are stuck and we will help you build a plan your team can act on.
Our market access work combines structured research, evidence analysis, payer and stakeholder intelligence, and relevant clinical input. Through access to a panel of 4,500+ payers and a network of physician consultants, we help clients assess the perspectives that can shape HTA, pricing, reimbursement, and access decisions.
Yes. Ingenious e-Brain has delivered 65+ projects globally, including 26+ engagements supporting Fortune 500 organizations across pharmaceutical and medtech sectors. Our work spans early evidence planning, HTA and pricing research, reimbursement pathway analysis, and post launch market intelligence.
The earlier, the better. Involving market access expertise during clinical development or pre launch planning can help identify evidence gaps, payer expectations, and reimbursement barriers before they become difficult to address. We also support established products facing pricing, reimbursement, competitive, or access related questions.
Each engagement is tailored to the asset, therapy area, product lifecycle stage, target markets, and strategic question. We define the scope, evidence requirements, research approach, outputs, and decision points around the priorities of the client team.
The team converted a complex evidence landscape into a clear set of priorities that our cross-functional teams could act on.
The work was rigorous, responsive, and highly practical. It gave us the confidence to refine our payer engagement plan.
We valued the combination of market-level detail and strategic direction, especially across markets with different access pathways.
